当前位置: 首页 > 详情页

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis.

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China [2]National Clinical Research Center for Geriatric Diseases, Beijing, China [3]Beijing Engineering Research Center for Nervous System Drugs, Beijing, China [4]Beijing Institute for Brain Disorders, Beijing, China [5]Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China
出处:
ISSN:

关键词: multiple sclerosis autoimmune diseases drug therapy neurodegenerative neuroprotective

摘要:
Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis of MS, its etiology still remains unclear. At present, there is no complete cure, but there are drugs that decelerate the progression of MS. Traditional therapies are disease-modifying drugs that control disease severity. MS drugs that are currently marketed mainly aim at the immune system; however, increasing attention is being paid to the development of new treatment strategies targeting the CNS. Further, the number of neuroprotective drugs is presently undergoing clinical trials and may prove useful for the improvement of neuronal function and survival. In this review, we have summarized the recent application of drugs used in MS treatment, mainly introducing new drugs with immunomodulatory, neuroprotective, or regenerative properties and their possible treatment strategies for MS. Additionally, we have presented Food and Drug Administration-approved MS treatment drugs and their administration methods, mechanisms of action, safety, and effectiveness, thereby evaluating their treatment efficacy.Copyright © 2021 Wei, Ma, Li and Zhang.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药学
JCR分区:
出版当年[2019]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China [2]National Clinical Research Center for Geriatric Diseases, Beijing, China [3]Beijing Engineering Research Center for Nervous System Drugs, Beijing, China [4]Beijing Institute for Brain Disorders, Beijing, China [5]Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China
通讯作者:
通讯机构: [1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China [2]National Clinical Research Center for Geriatric Diseases, Beijing, China [3]Beijing Engineering Research Center for Nervous System Drugs, Beijing, China [4]Beijing Institute for Brain Disorders, Beijing, China [5]Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17069 今日访问量:1 总访问量:919 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院